Headlines about Adamas Pharmaceuticals (NASDAQ:ADMS) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Adamas Pharmaceuticals earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 46.0138205983771 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news articles that may have effected Accern’s scoring:
- Adamas Pharmaceuticals Inc (ADMS) Receives Average Recommendation of “Buy” from Brokerages (americanbankingnews.com)
- Adamas Pharma Cmn (ADMS) Trending Activity with Technical … – ExpertGazette (expertgazette.com)
- Northland Securities Begins Coverage on Adamas Pharmaceuticals (ADMS) (americanbankingnews.com)
- Adamas Pharma Cmn (ADMS) Could Soar to $85 in a Year … – ExpertGazette (expertgazette.com)
- Can The Big Rally In Adamas Pharmaceuticals Continue? – Seeking Alpha (seekingalpha.com)
Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) opened at $35.93 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 8.35 and a quick ratio of 8.32. Adamas Pharmaceuticals has a twelve month low of $13.50 and a twelve month high of $38.22.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.03). The firm’s quarterly revenue was down 99.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.66) EPS. research analysts forecast that Adamas Pharmaceuticals will post -3.87 EPS for the current year.
ADMS has been the topic of a number of recent research reports. JMP Securities reissued an “outperform” rating and set a $33.00 target price (up from $29.00) on shares of Adamas Pharmaceuticals in a research report on Friday, August 25th. Zacks Investment Research cut shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 11th. BidaskClub raised shares of Adamas Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 23rd. ValuEngine raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $30.00 price target on shares of Adamas Pharmaceuticals in a report on Friday, September 1st. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $42.00.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Adamas Pharmaceuticals (ADMS) Share Price” was first published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://transcriptdaily.com/2017/12/03/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-adamas-pharmaceuticals-adms-share-price.html.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.